<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651922</url>
  </required_header>
  <id_info>
    <org_study_id>199A14PF</org_study_id>
    <nct_id>NCT02651922</nct_id>
  </id_info>
  <brief_title>Treatment of Patients Suffering From Nervous Restlessness With PASCOFLAIR®</brief_title>
  <official_title>Treatment of Patients Suffering From Nervous Restlessness With PASCOFLAIR®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pascoe Pharmazeutische Praeparate GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut für Empirische Gesundheitsökonomie, Prof. Dr. Dr.med. Reinhard Rychlik,Am Ziegelfeld 28,51399 Burscheid,Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pascoe Pharmazeutische Praeparate GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was carried out as a prospective, non-interventional study with the intention of
      subsequent process cost analyses (PCA) and also considers quality of life, drug misuse,
      dependence, adverse events and therapy satisfaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was carried out as a prospective, non-interventional study with the intention of
      subsequent process cost analyses (PCA) and also considers quality of life, drug misuse,
      dependence, adverse events and therapy satisfaction. Data were collected in collaboration
      with 22 physicians in Germany.

      The study was designed as a one armed non-interventional study. Patients had to suffer from
      nervous restlessness in order to be eligible for study documentation. Participants agreed to
      a medical treatment with PASCOFLAIR® of 12 weeks. In this context, documented patients could
      take PASCOFLAIR® at the first time or could have started within the past three months before
      the initial visit. Furthermore, documented patients had to be older than 18 years and must be
      able to read and understand the patient declaration of data protection and the declaration of
      consent. The patient must not be an alcoholic, must not be drug dependent and have no other
      types of addiction. Patients who were pregnant or breast-feeding were not eligible for study
      participation. Furthermore, patients showing hypersensitivity against passionflower extract
      or against other components of the medication were excluded. The signed declaration of
      consent of participating patients is available.

      The treatment of affected patients may not be documented, if a redemption (written or spoken)
      of the declaration of consent is existing or the patient takes Benzodiazepines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Symptom Inner Restlessness (Pre - Post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
    <description>Symptom was assessed in a Likert scale ranging from 0 &quot;no symptoms at all&quot; to 10 &quot;very severe symptoms&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Sleep Disturbance (Pre - Post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
    <description>Symptom was assessed in a Likert scale ranging from 0 &quot;no symptoms at all&quot; to 10 &quot;very severe symptoms&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Exhaustion (Pre - Post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
    <description>Symptom was assessed in a Likert scale ranging from 0 &quot;no symptoms at all&quot; to 10 &quot;very severe symptoms&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Fear (Pre - Post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
    <description>Symptom was assessed in a Likert scale ranging from 0 &quot;no symptoms at all&quot; to 10 &quot;very severe symptoms&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Lack of Concentration (Pre - Post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
    <description>Symptom was assessed in a Likert scale ranging from 0 &quot;no symptoms at all&quot; to 10 &quot;very severe symptoms&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Transpiration (Pre - Post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline )</time_frame>
    <description>Symptom was assessed in a Likert scale ranging from 0 &quot;no symptoms at all&quot; to 10 &quot;very severe symptoms&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Nausea (Pre - Post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation-approx. 12 weeks after baseline)</time_frame>
    <description>Symptom was assessed in a Likert scale ranging from 0 &quot;no symptoms at all&quot; to 10 &quot;very severe symptoms&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Trembling (Pre - Post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation - approx. 12 weeks after baseline)</time_frame>
    <description>Symptom was assessed in a Likert scale ranging from 0 &quot;no symptoms at all&quot; to 10 &quot;very severe symptoms&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Palpation (Pre - Post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
    <description>Symptom was assessed in a Likert scale ranging from 0 &quot;no symptoms at all&quot; to 10 &quot;very severe symptoms&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of BDEPQ (Benzodiazepine Dependence Questionnaire)</measure>
    <time_frame>Change from visit 2 (approx. 4 weeks after baseline) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
    <description>The Benzodiazepine Dependence Questionnaire (BDEPQ) is a 30 item self report questionnaire designed to measure dependence on benzodiazepine tranquilisers, sedatives and hypnotics. Items cover all aspects of the dependence syndrome with the exception of withdrawal symptoms. Each item is rated on a four point likert scale referring to experiences in the last month.
BDEPQ score ranges from 0 (no dependence) to 85 (most severe dependence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of RS-13 (Resilience Questionnaire) (Pre - Post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
    <description>RS-13 is a 13 items self Report questionnaire measure the resilience, which applies a reliance scale ranging from 13 (lowest stress resistance) to 91 (highest stress resistance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EQ-5D (Health Questionnaire) Scores (Pre - Post)</measure>
    <time_frame>Change from Baseline (before treatment) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
    <description>EQ-5D™ is a standardised instrument for use as a measure of health Outcome The EQ-5D assesses five aspects of QoL: mobility, self-care, usual activity, pain/discomfort and anxiety/depression. An EQ-5D profile score of 0 points represents the worst QoL (death), while 1 point stands for full health. Data analysis was performed according to the EuroQol manual. The EQ-VAS ranges from 0 (worst QoL) to 100 (best QoL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of EQ-5D VAS Scores (Pre - Post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
    <description>VAS values (Quality of Life) range from 0 (very poor) to 100 (best possible state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability Assess Using a 5 Point Scale</measure>
    <time_frame>Evaluation of Tolerability on visit 3 (appr. 12 weeks after baseline)</time_frame>
    <description>Assessment of tolerability using a 5 point scale (very good, good, satisfactory, bad, very bad)</description>
  </secondary_outcome>
  <enrollment type="Actual">154</enrollment>
  <condition>Nervous Restlessness</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients had to suffer from nervous restlessness in order to be eligible for study
        documentation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients suffering from nervous restlessness

        Exclusion Criteria:

          -  Age &lt; 18 years and must be able to read and understand the patient declaration of data
             protection and the declaration of consent

          -  alcoholics, drug pending, addictive disorder

          -  pregnancy or lactating

          -  patients showing hypersensitivity against passionflower extract or against other
             components of the medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <results_first_submitted>April 21, 2016</results_first_submitted>
  <results_first_submitted_qc>April 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2017</results_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nervous restlessness</keyword>
  <keyword>Pascoflair</keyword>
  <keyword>Passiflora incarnata</keyword>
  <keyword>Benzodiazepine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PASCOFLAIR Group (Verum)</title>
          <description>Patients who were treated with PASCOFLAIR</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>due to exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 156 patients participated in the study. Two patients were excluded from the analysis, because they received Benzodiazepines (Tavor, Lexostad). One patient was 17 years of age when documented in the study. The overall study population considered in the analyses was 154 patients.</population>
      <group_list>
        <group group_id="B1">
          <title>PASCOFLAIR Group (Verum)</title>
          <description>Patients who were treated with PASCOFLAIR</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="154"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>2 missinig data</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.9" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Symptom Inner Restlessness (Pre - Post)</title>
        <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
        <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 146 patients showed this symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>PASCOFLAIR Group (Verum)</title>
            <description>Patients who were treated with PASCOFLAIR</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Inner Restlessness (Pre - Post)</title>
          <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
          <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 146 patients showed this symptom.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>detoriated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Sleep Disturbance (Pre - Post)</title>
        <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
        <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 146 patients showed this symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>PASCOFLAIR Group (Verum)</title>
            <description>Patients who were treated with PASCOFLAIR</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Sleep Disturbance (Pre - Post)</title>
          <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
          <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 146 patients showed this symptom.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Exhaustion (Pre - Post)</title>
        <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
        <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 145 patients showed this symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>PASCOFLAIR Group (Verum)</title>
            <description>Patients who were treated with PASCOFLAIR</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Exhaustion (Pre - Post)</title>
          <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
          <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 145 patients showed this symptom.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>detoriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Fear (Pre - Post)</title>
        <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
        <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 133 patients showed this symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>PASCOFLAIR Group (Verum)</title>
            <description>Patients who were treated with PASCOFLAIR</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Fear (Pre - Post)</title>
          <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
          <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 133 patients showed this symptom.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>detoriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Lack of Concentration (Pre - Post)</title>
        <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
        <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 142 patients showed this symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>PASCOFLAIR Group (Verum)</title>
            <description>Patients who were treated with PASCOFLAIR</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Lack of Concentration (Pre - Post)</title>
          <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
          <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 142 patients showed this symptom.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>detoriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Transpiration (Pre - Post)</title>
        <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline )</time_frame>
        <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 121 patients showed this symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>PASCOFLAIR Group (Verum)</title>
            <description>Patients who were treated with PASCOFLAIR</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Transpiration (Pre - Post)</title>
          <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
          <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 121 patients showed this symptom.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>detoriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Nausea (Pre - Post)</title>
        <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation-approx. 12 weeks after baseline)</time_frame>
        <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 92 patients showed this symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>PASCOFLAIR Group (Verum)</title>
            <description>Patients who were treated with PASCOFLAIR</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Nausea (Pre - Post)</title>
          <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
          <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 92 patients showed this symptom.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchnaged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>detoriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Trembling (Pre - Post)</title>
        <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation - approx. 12 weeks after baseline)</time_frame>
        <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 108 patients showed this symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>PASCOFLAIR Group (Verum)</title>
            <description>Patients who were treated with PASCOFLAIR</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Trembling (Pre - Post)</title>
          <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
          <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 108 patients showed this symptom.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deterioreated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Palpation (Pre - Post)</title>
        <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
        <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 130 patients showed this symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>PASCOFLAIR Group (Verum)</title>
            <description>Patients who were treated with PASCOFLAIR</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Palpation (Pre - Post)</title>
          <description>Symptom was assessed in a Likert scale ranging from 0 “no symptoms at all” to 10 “very severe symptoms”</description>
          <population>If a symptom was rated 0, it was considered nonexistent. For any other rating (1 to 10) the symptom was considered existent.
Only 130 patients showed this symptom.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of BDEPQ (Benzodiazepine Dependence Questionnaire)</title>
        <description>The Benzodiazepine Dependence Questionnaire (BDEPQ) is a 30 item self report questionnaire designed to measure dependence on benzodiazepine tranquilisers, sedatives and hypnotics. Items cover all aspects of the dependence syndrome with the exception of withdrawal symptoms. Each item is rated on a four point likert scale referring to experiences in the last month.
BDEPQ score ranges from 0 (no dependence) to 85 (most severe dependence).</description>
        <time_frame>Change from visit 2 (approx. 4 weeks after baseline) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
        <population>For patient with less than 75% items answered the BDEPQ-Score was not calculated.
For only 132 patients Score was calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>PASCOFLAIR Group (Verum)</title>
            <description>Patients who were treated with PASCOFLAIR</description>
          </group>
        </group_list>
        <measure>
          <title>Change of BDEPQ (Benzodiazepine Dependence Questionnaire)</title>
          <description>The Benzodiazepine Dependence Questionnaire (BDEPQ) is a 30 item self report questionnaire designed to measure dependence on benzodiazepine tranquilisers, sedatives and hypnotics. Items cover all aspects of the dependence syndrome with the exception of withdrawal symptoms. Each item is rated on a four point likert scale referring to experiences in the last month.
BDEPQ score ranges from 0 (no dependence) to 85 (most severe dependence).</description>
          <population>For patient with less than 75% items answered the BDEPQ-Score was not calculated.
For only 132 patients Score was calculated.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of RS-13 (Resilience Questionnaire) (Pre - Post)</title>
        <description>RS-13 is a 13 items self Report questionnaire measure the resilience, which applies a reliance scale ranging from 13 (lowest stress resistance) to 91 (highest stress resistance).</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCOFLAIR Group (Verum)</title>
            <description>Patients who were treated with PASCOFLAIR</description>
          </group>
        </group_list>
        <measure>
          <title>Change of RS-13 (Resilience Questionnaire) (Pre - Post)</title>
          <description>RS-13 is a 13 items self Report questionnaire measure the resilience, which applies a reliance scale ranging from 13 (lowest stress resistance) to 91 (highest stress resistance).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in EQ-5D (Health Questionnaire) Scores (Pre - Post)</title>
        <description>EQ-5D™ is a standardised instrument for use as a measure of health Outcome The EQ-5D assesses five aspects of QoL: mobility, self-care, usual activity, pain/discomfort and anxiety/depression. An EQ-5D profile score of 0 points represents the worst QoL (death), while 1 point stands for full health. Data analysis was performed according to the EuroQol manual. The EQ-VAS ranges from 0 (worst QoL) to 100 (best QoL).</description>
        <time_frame>Change from Baseline (before treatment) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCOFLAIR Group (Verum)</title>
            <description>Patients who were treated with PASCOFLAIR</description>
          </group>
        </group_list>
        <measure>
          <title>Change in EQ-5D (Health Questionnaire) Scores (Pre - Post)</title>
          <description>EQ-5D™ is a standardised instrument for use as a measure of health Outcome The EQ-5D assesses five aspects of QoL: mobility, self-care, usual activity, pain/discomfort and anxiety/depression. An EQ-5D profile score of 0 points represents the worst QoL (death), while 1 point stands for full health. Data analysis was performed according to the EuroQol manual. The EQ-VAS ranges from 0 (worst QoL) to 100 (best QoL).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deterioreated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of EQ-5D VAS Scores (Pre - Post)</title>
        <description>VAS values (Quality of Life) range from 0 (very poor) to 100 (best possible state).</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCOFLAIR Group (Verum)</title>
            <description>Patients who were treated with PASCOFLAIR</description>
          </group>
        </group_list>
        <measure>
          <title>Change of EQ-5D VAS Scores (Pre - Post)</title>
          <description>VAS values (Quality of Life) range from 0 (very poor) to 100 (best possible state).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability Assess Using a 5 Point Scale</title>
        <description>Assessment of tolerability using a 5 point scale (very good, good, satisfactory, bad, very bad)</description>
        <time_frame>Evaluation of Tolerability on visit 3 (appr. 12 weeks after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCOFLAIR Group (Verum)</title>
            <description>Patients who were treated with PASCOFLAIR</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability Assess Using a 5 Point Scale</title>
          <description>Assessment of tolerability using a 5 point scale (very good, good, satisfactory, bad, very bad)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>very bad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The observational period was from September 2014 till June 2015. Per Patient were adrs collected for the treatment period (12 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PASCOFLAIR Group (Verum)</title>
          <description>Patients who were treated with PASCOFLAIR</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.0</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness in limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Inga Trompetter and Jennifer Lebert</name_or_title>
      <organization>PASCOE Pharmazeutische Präparate GmbH</organization>
      <phone>0049-(0)641-7960-955</phone>
      <email>Jennifer.lebert@pascoe.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

